Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anteris Technologies Global Corp. (AVR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, giving investors a detailed view of its structural heart business and capital markets activity. As a medical instruments and supplies company focused on the DurAVR Transcatheter Heart Valve (THV) System, Anteris uses its filings to describe its technology, clinical programs and financial profile.
Through registration statements such as the Form S‑1, readers can review the company’s business overview, including its description of DurAVR THV as a balloon‑expandable biomimetic aortic valve, the role of its proprietary ADAPT tissue technology and the design of the ComASUR balloon‑expandable delivery system. These filings also outline the PARADIGM Trial, a global prospective randomized controlled trial comparing DurAVR THV to commercially available TAVR devices, and explain how the trial is intended to support a future Premarket Approval application and CE Mark progress.
Current reports on Form 8‑K document material events such as FDA IDE approval for PARADIGM, first patient enrollment and treatment in the pivotal trial, clinical data presentations, capital raising transactions involving common stock, CHESS Depositary Interests and warrants, and other corporate developments. Definitive proxy statements on Schedule 14A provide detail on the annual meeting agenda, director elections, equity incentive awards and stockholder voting procedures.
On Stock Titan, these filings are updated in near real time from EDGAR and can be paired with AI‑generated summaries that highlight key points from lengthy documents. Users can quickly locate quarterly reports on Form 10‑Q, annual reports on Form 10‑K (when filed), 8‑K event disclosures and registration statements, and use AI‑assisted explanations to understand complex sections such as risk factors, clinical trial descriptions, capital structure and equity compensation proposals.
For those analyzing AVR, the filings page offers a structured way to follow how Anteris presents its structural heart strategy, clinical evidence plans and financing arrangements to regulators and investors.
Anteris Technologies Global Corp. (AVR) furnished quarterly results materials. The company submitted an 8-K noting it filed its Form 10-Q for the quarter ended September 30, 2025, and furnished an accompanying ASX Results Announcement and an ASX Announcement. These materials include unaudited and other historical financial information for the quarter. The exhibits (99.1 and 99.2) are furnished under Item 2.02 and are not deemed filed or incorporated by reference unless a later filing expressly states otherwise.
Anteris Technologies Global Corp. (AVR) reported a third‑quarter net loss and flagged going‑concern uncertainty. Net sales were $429 thousand, while operating loss reached $22.3 million. R&D expense was $16.8 million as the company advanced the DurAVR® transcatheter heart valve program and pivotal PARADIGM Trial preparations. Selling, general and administrative expense was $5.8 million.
The company recorded a net loss after income tax of $22.2 million for the quarter and $65.2 million year‑to‑date. Cash, cash equivalents and restricted cash were $9.1 million as of September 30, 2025, with net cash used in operating activities of $59.3 million for the nine months, leading management to note “substantial doubt” about continuing as a going concern. Stockholders’ equity was $3.7 million.
Subsequent to quarter‑end, Anteris completed a private placement generating approximately $25.2 million in gross proceeds and received key regulatory milestones for its PARADIGM Trial, including the first European clearance in Denmark and FDA approval to initiate the U.S. IDE study. The trial is designed to support a future PMA and parallel CE Mark efforts.
Anteris Technologies Global Corp. (AVR) announced its 2025 Annual Meeting of Stockholders to be held on December 3, 2025 at 5:00 p.m. Central time, in Brisbane and via webcast at www.virtualshareholdermeeting.com/AVR2025. Stockholders of record as of October 30, 2025 may attend, vote, and submit questions. Holders of CHESS Depositary Interests (CDIs) may attend and direct votes in advance through CHESS Depositary Nominees but are not eligible to vote during the meeting.
Thirteen proposals are up for vote, including electing John Seaberg and Gregory Moss as Class I directors, ratifying KPMG as independent auditor for the fiscal year ending December 31, 2025, approving equity awards tied to the IPO—such as 1,000,000 RSUs to Wayne Paterson and RSU grants to non‑employee directors—and approving adjustments and amendments to previously granted stock options under ASX Listing Rule 6.23.4.
Voting mechanics: Proposal One is decided by plurality; most others require a majority of shares present and entitled to vote; Proposal Two is a routine matter permitting broker discretionary voting. Shares outstanding were 38,409,506 as of the record date. The Board recommends voting FOR all proposals.
Anteris Technologies Global Corp. furnished a Regulation FD update via Form 8‑K announcing that the U.S. FDA approved its DurAVR® Transcatheter Heart Valve Global Pivotal Trial, known as the PARADIGM Trial. The company attached the related press release as Exhibit 99.1, and the information was furnished, not filed, under the Exchange Act.
Anteris Technologies Global Corp. (AVR) announced its 2025 Annual Meeting for December 3, 2025 at 5:00 p.m. Central time in Brisbane with a concurrent webcast at www.virtualshareholdermeeting.com/AVR2025. The record date is October 30, 2025.
Stockholders will vote on 13 proposals. Key items include electing two Class I directors (John Seaberg and Gregory Moss) and ratifying KPMG as independent auditor for the fiscal year ending December 31, 2025. Several equity awards are up for approval under ASX Listing Rule 10.14: 1,000,000 RSUs to Wayne Paterson, 83,333 RSUs to John Seaberg, 41,666 RSUs to Stephen Denaro, and 52,742 RSUs each to Gregory Moss and David Roberts. Additional annual director grants by value include $250,000 to Seaberg, $125,000 to Denaro, and $61,644 each to Moss and Roberts.
Two proposals under ASX Listing Rule 6.23.4 seek approval for adjustments to certain option exercise prices and amendments to prior option terms. The Board recommends voting FOR all proposals. Holders of CHESS Depositary Interests receive notice and may vote in advance by directing CDN; CDI holders cannot vote during the meeting unless appointed as CDN’s proxy.
Anteris Technologies Global Corp. (AVR) furnished an update via Form 8-K stating that the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve global pivotal PARADIGM trial for severe calcific aortic stenosis.
The company noted this information is being furnished, not filed, under the Exchange Act. An accompanying press release dated October 27, 2025 was included as Exhibit 99.1.
Anteris Technologies Global Corp. (AVR) closed a private common stock offering, issuing 2,346,936 shares of common stock and five-year warrants to purchase 2,346,936 shares, generating approximately US$11.5 million in gross proceeds. The securities were sold at US$4.90 per share with an accompanying warrant, and were issued without registration under Section 4(a)(2) and Rule 506.
The company had earlier expanded the deal by adding 102,040 additional shares on the same terms. The warrants are exercisable commencing six months following the date of issuance. Anteris plans to file a registration statement to cover the resale of the shares and the shares issuable upon exercise of the warrants, as well as CDIs and related warrant shares from a concurrently arranged CDI offering priced at A$7.50 per CDI.
Anteris Technologies Global Corp. (AVR) announced a private placement financing, agreeing to sell 2,244,896 shares of common stock with five-year warrants and 2,788,064 CHESS Depositary Interests (CDIs) with five-year warrants. The common stock is priced at US$4.90 per share and accompanying warrant; the CDIs are priced at A$7.50 per CDI and accompanying warrant. The company expects aggregate gross proceeds of approximately US$25 million.
The common stock offering is expected to close on or around October 27, 2025, and the CDI offering to settle on or around October 30, 2025, subject to customary conditions. Warrants become exercisable six months after issuance, at an exercise price of $7.50 per common share and A$11.50 per CDI. The company will file a registration statement covering the resale of the securities and the shares underlying the warrants and CDIs. The offerings rely on Section 4(a)(2) and Rule 506 of Regulation D (for common stock) and Regulation S (for CDIs). Evolution Capital Pty Ltd, lead manager for the CDI tranche, will receive 250,000 CDI warrants.
Anteris Technologies Global Corp. (AVR) announced it will hold its first Annual Meeting of Stockholders on December 3, 2025 (December 4, 2025 in Australia). Stockholders of record as of October 30, 2025 (October 31, 2025 in Australia) will be entitled to vote.
Stockholder proposals for inclusion in the proxy materials under Rule 14a-8 must be received by the Company’s Secretary no later than October 25, 2025 at 11:59 p.m. Eastern time (2:59 p.m. AEDT on October 26, 2025 in Australia) and must comply with SEC rules, Delaware law, and the Company’s Amended and Restated Bylaws. Additional details, including exact time and matters to be voted on, will appear in the forthcoming proxy statement.
FAQ
What is the current stock price of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
What is the market cap of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
